Furthermore, to our knowledge, this is the first case describing a <i>RET</i> fusion-positive (<i>RET</i>+) NSCLC patient treated with a modified selpercatinib dosage outside the drug data sheet and demonstrating a safe and effective use. Here, RET is linked to non-small cell lung carcinoma.